Nuvigil is owned by Cephalon.
Nuvigil contains Armodafinil.
Nuvigil has a total of 4 drug patents out of which 0 drug patents have expired.
Nuvigil was authorised for market use on 15 June, 2007.
Nuvigil is available in tablet;oral dosage forms.
The generics of Nuvigil are possible to be released after 18 June, 2024.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7132570 | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Dec, 2023
(6 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(5 months from now) | |
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(11 months from now) | |
US7132570 (Pediatric) | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Jun, 2024
(1 year, 10 days from now) |
Drugs and Companies using ARMODAFINIL ingredient
Market Authorisation Date: 15 June, 2007
Treatment: NA
Dosage: TABLET;ORAL
17
United States
8
China
8
European Union
6
Hong Kong
5
Japan
5
Spain
4
Canada
4
New Zealand
4
Australia
3
Korea, Republic of
3
Brazil
3
Taiwan
3
Malaysia
3
Argentina
3
Mexico
3
Norway
3
South Africa
3
Israel
2
France
2
Chile
2
Poland
2
Slovenia
2
Ukraine
2
Iceland
2
Germany
2
Denmark
2
EA
2
Austria
2
Portugal
2
Cyprus
1
Egypt
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic